Trial Profile
Cancer Pain Management With Hydromorphone HCl ORal Osmotic System in Korean Cancer Patient: Evaluation of Its Clinical Usefulness in Reduction of Breakthrough Pain Medication Frequency.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2013
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Janssen
- 09 Dec 2009 Actual number of patients (73) added as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.